GlassScriptPhysician profile
Brandon James Bryant
NPI 1174554398
$290,374.14
in general payments reported to CMS, 2019-2025
20 companies · $53K in 2025
The $53K reported for 2025 was more than what 95% of Sports Medicine (Orthopaedic Surgery) providers received nationally (typical 2025 total: $686).
See the full distribution for Sports Medicine (Orthopaedic Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,571 · 2020: $12K · 2021: $13K · 2022: $29K · 2023: $122K · 2024: $56K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $90K · Acquisitions: $83K · Consulting Fee: $44K · Food and Beverage: $6,103 · Travel and Lodging: $5,130 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $90,316.22 |
| Acquisitions | $83,350.99 |
| Consulting Fee | $43,973.50 |
| Food and Beverage | $6,103.44 |
| Travel and Lodging | $5,129.56 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zimmer Biomet Holdings, INC. | $145,903.03 | 2019-2025 | Tapestry, Tricera Handpiece, Activbraid |
| Anika Therapeutics, INC. | $101,736.85 | 2021-2025 | Actiflip, Actiflip, Revomotion |
| Smith+Nephew, INC. | $16,684.51 | 2019-2025 | Acufex Meniscal Root Repair, Q-Fix, Novostitch |
| Ossio INC | $11,694.18 | 2023-2024 | |
| Parcus Medical, LLC | $4,556.42 | 2019-2020 | |
| Embody, INC. | $3,054.84 | 2019-2023 | |
| Supreme Orthopedic Systems, LLC | $1,880.63 | 2019-2025 | |
| Arcuro Medical INC | $1,601.67 | 2022-2024 | Superball |
| Arthrex, INC. | $1,059.70 | 2024 | |
| International Life Sciences | $771.43 | 2023 | |
| Xiros INC | $330.50 | 2023 | Pitch-Patch, N/A, Infinity-Lock 5 |
| Linvatec Corporation | $268.73 | 2025 | Biobrace 23mm |
| Djo, LLC | $253.76 | 2023-2024 | Procare, Aircast, Donjoy |
| Stryker Corporation | $157.93 | 2021-2024 | Flexible Guide Pin (Stryker Acl Versitomic) |
| Edwards Lifesciences Corporation | $123.31 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abanza INC. | $118.53 | 2025 | Washercap Fixation System 10mm, Washercap Mini Fixation System 4.5mm |
| Axogen | $80.85 | 2023 | Avance Nerve Graft |
| Lima USA, INC. | $42.66 | 2023 | Smr Shoulder |
| Davol INC. | $42.00 | 2024 | Phasix Mesh |
| Theragen, INC. | $12.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$287,420.35 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.